BioNTech now has more than 25 phase 2 and phase 3 oncology trials underway, with 15 phase 3 trials targeted by the end of 2026. Pumitamig is being tested across lung, breast, gastric, and kidney cancers, giving the drug multiple paths to commercial success.
Read on fool.com